Diffuse Midline Glioma H3 K27M-Mutant Overview

Save information for later
Sign Up

Learn About Diffuse Midline Glioma H3 K27M-Mutant

View Main Condition: Brain Tumor

What is the definition of Diffuse Midline Glioma H3 K27M-Mutant?
Diffuse intrinsic pontine glioma (DIPG) is a type of aggressive brain tumor that occurs in the pons, part of the brainstem. The pons is important for many bodily functions, including regulating breathing, heart rate, bladder control, balance, and more.  Diffuse intrinsic pontine glioma primarily affects children, with roughly 150-300 new diagnoses per year. 
What are the causes of Diffuse Midline Glioma H3 K27M-Mutant?
The cause of diffuse intrinsic pontine glioma is not currently known. Research is being done to identify if certain genetic mutations may be causing DIPG. 
What are the symptoms of Diffuse Midline Glioma H3 K27M-Mutant?
Symptoms of diffuse intrinsic pontine glioma often develop quickly. Symptoms may include poor coordination, arm and leg weakness, as well as difficulty controlling eye movements and facial expressions. Some individuals may experience difficulty speaking or eating as well. 
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Diffuse Midline Glioma H3 K27M-Mutant?
The main treatments for diffuse intrinsic pontine glioma currently include radiation therapy and experimental chemotherapy.  Radiation therapy is generally used for newly diagnosed DIPG. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Various clinical trials have shown that routine chemotherapy is not effective for treating DIPG. Newer treatments combine chemotherapy with biologic therapy that directly target the tumor.  Because of the tumor's location in the brainstem, it is rarely possible to perform surgery without risk of causing neurological damage. 
Who are the top Diffuse Midline Glioma H3 K27M-Mutant Local Doctors?
Mark M. Souweidane
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Mark M. Souweidane
Neurosurgery | General Surgery
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Mark M. Souweidane
Neurosurgery | General Surgery

Weill Cornell Medicine Brain & Spine Center

1305 York Ave, 9th Floor, 
New York, NY 
212-746-2363
Experience:
37+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Souweidane is a General Surgeon and a Neurosurgery provider in New York, New York. Dr. Souweidane has been practicing medicine for over 37 years and is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Gliomatosis Cerebri, Brain Tumor, Craniopharyngioma, and Osteotomy. Dr. Souweidane is currently accepting new patients.

Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Katherine Warren
Pediatric Hematology Oncology | Pediatrics
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Katherine Warren
Pediatric Hematology Oncology | Pediatrics
450 Brookline Ave, 
Boston, MA 
617-632-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Katherine Warren is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Boston, Massachusetts. Dr. Warren and is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Gliomatosis Cerebri.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Alberto Broniscer
Pediatric Hematology Oncology | Pediatrics
Elite in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Alberto Broniscer
Pediatric Hematology Oncology | Pediatrics
262 Danny Thomas Place, Ms 0515, St. Jude Children's Research Hospital, 
Memphis, TN 
901-595-3006
Languages Spoken:
English
See accepted insurances

Alberto Broniscer is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Memphis, Tennessee. Dr. Broniscer and is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Gliomatosis Cerebri.

View All Doctors
What is the outlook (prognosis) for Diffuse Midline Glioma H3 K27M-Mutant?
The prognosis for diffuse intrinsic pontine glioma is very poor. Although there is no cure, a small percentage of patients survive.
What are the latest Diffuse Midline Glioma H3 K27M-Mutant Clinical Trials?
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Who is this study for: Patients with recurrent, progressive or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and CNS tumors harboring MET aberrations
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1

Summary: This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
Enrollment Status: Recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

View All Clinical Trials
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.